MedinCell announced that its long-acting injectable malaria treatment is ready to enter into the stages of regulatory development.
Montpellier, France-based MedinCell conducted an in vivo proof of concept on cattle that demonstrated three-month mosquitocidal effectiveness in the injectable, long-acting formulation of Ivermectin using the company’s BEPO delivery technology.
Get the full story at our sister site, Drug Delivery Business News.